-Deccan Chronicle Prime Minister Narendra Modi may be patting himself on the back because President Barack Obama has agreed to India's position on food stockholding norms in World Trade Organisation (WTO). However, New Delhi seems to be bending over backwards to accommodate the American government and giant multinational corporations (MNCs) in the pharmaceutical industry, which will work to the detriment of our country's interests. In less than six months, the Modi government...

-The Hindu Business Line Report lauds rapid progress in health indicators, especially in Maharashtra India is making rapid strides in overcoming the problem of malnutrition, with the number of stunted children under the age of five declining by over 10 million, says a ‘Global Nutrition Report'. The "first-ever comprehensive narrative on global health and country-level progress toward reducing malnutrition", brought out by a consortium of nations, organisations, researchers, and academics, covers each of...

-Economic and Political Weekly The current regime seeks to reform labour laws with the understanding that these reforms will improve industrial growth and expand the possibilities of enterprise. However, there is already ample evidence from within India that this obsession with reforming labour law, particularly in the way the government has done it till now, will not take us any closer in creating more jobs or a healthy industrial sector. These...

-The Hindu India has dramatically reduced not only the number of underweight children but also the numbers of stunted and wasted children, new details of yet-unreleased official nutrition data show. The proportion of children under the age of five who are stunted has fallen from 48 per cent to 39 per cent between 2005-6 and 2013-14, the new numbers show, meaning that India now has 14.5 million fewer stunted children. Stunting is...

-Down to Earth Pharma company's strategy of different prices for different countries to affect quality treatment of 185 million people infected with Hepatitis C worldwide Health activists and agencies on Tuesday criticised leading pharmaceutical company Bristol-Myers Squibb (BMS)'s commercial strategy to sell new Hepatitis C medicine Daclatasvir, stating it would exclude a large number of patients who cannot afford expensive treatment. BMS had announced that it would create a tiered pricing strategy for...